Showing results (451-460 of 587) with videos related to

Sort By:
Pageof 59
Targeted Oncology|October 18, 2021
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and OutcomesChristos Chouaid, Thomas Filleron, Didier Debieuvre, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological CorrelatesFilippo G Dall'Olio, Wael Zrafi, Veronique Roelants, et al.
Cancer Discovery|April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSeshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
Cell|June 21, 2024
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcomeLisa Derosa, Valerio Iebba, Carolina Alves Costa Silva, et al.
The Lancet. Oncology|April 16, 2016
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialDavid Planchard, Tae Min Kim, Julien Mazieres, et al.
The New England Journal of Medicine|November 8, 2023
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLCDavid Planchard, Pasi A Jänne, Ying Cheng, et al.
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2019
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France studySébastien Couraud, Fabrice Barlesi, Clara Fontaine-Deraluelle, et al.
Pageof 59